Suche icon

Urologische Tumoren

PCO-Studie

CARAT

MoonRISe - 1

  • Status: activ
  • The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
  • Kurzinformation
  • Ansprechpartner:
    Prof. Dr. Jens Bedke
    Telefon: 0711 278-54564
    E-Mail: j.bedke@klinikum-stuttgart.de
  • Studienzentrale
    Telefon: 0711 278-30410, -30411, -30414
    E-Mail: scc-studienzentrale@klinikum-stuttgart.de

SGNDV-003

  • Status: aktiv
  • This study is being done to learn about urothelial cancers that make HER2 and how that affects treatment choices for participants with urothelial cancer. During this study, the medical and health records of participants will be reviewed to learn more about their health. Participants will have urothelial cancer that has grown in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
  • Kurzinformation 
  • Ansprechpartner:
    Prof. Dr. Jens Bedke
    Telefon: 0711 278-54564
    E-Mail: j.bedke@klinikum-stuttgart.de
  • Studienzentrale
    Telefon: 0711 278-30410, -30411, -30414
    E-Mail: scc-studienzentrale@klinikum-stuttgart.de

V940-004

  • Status: aktiv - nicht rekrutierend
  • A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma
  • Kurzinformation
  • Ansprechpartner:
    Prof. Dr. Jens Bedke
    Telefon: 0711 278-54564
    E-Mail: j.bedke@klinikum-stuttgart.de
  • Studienzentrale
    Telefon: 0711 278-30410, -30411, -30414
    E-Mail: scc-studienzentrale@klinikum-stuttgart.de